Corcept Therapeutics Incorporated
NASDAQ:CORTBiotechnology
-$1.96 today
- Market cap
- $7.42B
- Beta
- 0.50
- P/E (TTM)
- 178.2
- EPS (TTM)
- $0.46
Volume 0.74M
Average 1.41M
CORT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Corcept Therapeutics IncorporatedNASDAQ: CORT
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses declines year over year
Q2 FY2026 other income / expenses of $4.63M fell 7.7% year over year, ahead of the -17.7% change in trailing-twelve-month other income / expenses. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +82.6% a year.
Context
- Other income / expenses amounted to 2.8% of revenue in FY2025, down 0.8 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -7.7% holds above the trailing-twelve-month pace of -17.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 21.67M USD
- Year-over-year change
- -11.7%
- 4-year CAGR
- +153.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.67M | -11.7% |
| FY2024 | 2024-12-31 | 24.54M | +42.1% |
| FY2023 | 2023-12-31 | 17.28M | +385.7% |
| FY2022 | 2022-12-31 | 3.56M | +572.4% |
| FY2021 | 2021-12-31 | 529K | — |
Other Income / Expenses vs competitors
How CORT compares with its peers on the latest reported figures
- CORT's LTM Jun 2026 other income / expenses of $19.96M is the highest of the 3 companies compared; the peer median is $6.03M.
- Its year-over-year change of -17.7% is the 2nd highest of 3, against a peer median of -88.8%.
- Other income / expenses amounts to 2.4% of revenue for CORT.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $19.96M | -17.7% | +82.6% | 2.4% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $15.24M | +46.9% | — | — |
| LTM Mar 2026 | -$3.18M | -224.4% | — | — | |
| Peer median (excluding CORT) | $6.03M | -88.8% | — | — | |
Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 365.98M | 401.86M | 482.38M | 675.04M | 761.41M |
| Cost of Revenue | 5.28M | 5.39M | 6.48M | 10.88M | 12.98M |
| Gross Profit | 360.7M | 396.47M | 475.89M | 664.16M | 748.43M |
| Gross Margin | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% |
| Research & Development | 113.86M | 130.99M | 184.35M | 246.89M | 254.91M |
| Selling, General & Admin | 122.36M | 152.85M | 184.26M | 280.32M | 448.73M |
| Operating Expenses | 236.22M | 283.84M | 368.61M | 527.21M | 703.63M |
| Depreciation & Amortization | 3.07M | 3.45M | 2.36M | 1.34M | 1.89M |
| EBITDA | 127.95M | 119.64M | 126.92M | 162.83M | 68.35M |
| EBITDA Margin | 35.0% | 29.8% | 26.3% | 24.1% | 9.0% |
| Operating Income | 124.48M | 112.63M | 107.28M | 136.95M | 44.8M |
| Operating Margin | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Interest Income | 529K | 3.56M | 17.28M | 24.54M | 21.67M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 529K | 3.56M | 17.28M | 24.54M | 21.67M |
| Income Before Tax | 125.01M | 116.19M | 124.56M | 161.49M | 66.46M |
| Pre-Tax Margin | 34.2% | 28.9% | 25.8% | 23.9% | 8.7% |
| Income Tax Expense | 12.49M | 14.77M | 18.42M | 20.28M | (33.19M) |
| Net Income | 112.51M | 101.42M | 106.14M | 139.73M | 99.65M |
| Net Margin | 30.7% | 25.2% | 22.0% | 20.7% | 13.1% |
| EPS (Basic) | 0.97 | 0.95 | 1.02 | 1.35 | 0.95 |
| EPS (Diluted) | 0.89 | 0.87 | 0.94 | 1.23 | 0.82 |
| Weighted Avg Shares | 115.65M | 106.79M | 103.56M | 103.23M | 103.86M |
| Weighted Avg Shares (Diluted) | 125.96M | 115.97M | 111.74M | 113.48M | 119.99M |
Corcept Therapeutics Incorporated
NASDAQ:CORT
Intrinsic Alpha fair value
Locked
Current Price
$67.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.